Capricor Craters 67% as FDA Questions Deramiocel Data

Capricor lost the bulk of its value before lunch — and the company didn't release a single line of data. The FDA's own reviewers did the damage, two days before the panel even sits down.

Add a two-point-two billion dollar cash deal out of argenx, a chief executive walking out at Legend Biotech, and a sector that shrugged at all of it. Monday came in hot. Let's get into it.

Welcome to The Pharma Closeout for Monday, July 27th. I'm Alex Mercer.

And I'm Maya Patel.

Capricor Therapeutics down roughly sixty-seven percent in early trading — that number is GuruFocus's. No trial readout. No safety event. FDA briefing documents hit the wire ahead of Wednesday's advisory committee on deramiocel, the company's cell therapy in Duchenne muscular dystrophy, and the stock did the rest. We had Wednesday's meeting on the board yesterday as a setup. Today it stopped being a setup.

And the wires didn't tell the same story about why. Endpoints reported the agency saying the therapy lacks efficacy. BioPharma Dive framed it as FDA scientists questioning the data. One aggregator ran it as a safety concern — single source, and I'd set that one aside. Three outlets say efficacy. That's the fight.

Here's what was riding on Wednesday. The BLA has been under review. The committee was announced earlier in the summer. It's live-streamed. And Duchenne has been the hardest room in rare disease this cycle — the agency spent the last year getting less flexible, not more.

Now the part worth slowing down for. Capricor answered this morning, and the response is not about the drug. It's about which document governs. They say the agency's post-hoc analyses run off an earlier version of the statistical analysis plan — which they describe as an unsigned, incomplete internal draft that went obsolete the moment cohort B was added. Their results, they say, are governed by a later, locked version of the analysis plan, finalized before unblinding. HOPE-3 hit on its key secondary measure, with a supportive cardiac function benefit. That's Linda Marbán's position, in writing, today.

So this is a genuine dispute. Not spin.

Genuine — and almost never winnable. When the sponsor and the agency are arguing about which plan applies, the panel has already read the reviewers' version. The company spends its allotted minutes trying to drag the room back to a document nobody in it has internalized. That's the least favorable argument you can walk in holding.

Which is exactly what the market priced. Read the briefing document, call the vote, move on.

But that's where I'd push back. Briefing documents aren't a decision, and the vote isn't binding — the agency overrides panels, in both directions. What actually worries me is narrower and worse than the headline. The reviewers didn't just critique Capricor's analysis. They ran their own. Regulators do that when they've stopped accepting the sponsor's framework at all.

That's a fair correction. I'll take it. So the sell-off isn't wrong — it's aimed at the wrong event.

Then here's the sharper version. This was never "deramiocel loses Wednesday." The burden just moved from persuading a panel to defending the analytical foundation underneath the entire application. That's a longer road than a vote, and it doesn't close on Wednesday no matter how the hands go up.

Competitive read, and this one travels. If you're running strategy on any cell or gene therapy in rare neuromuscular disease, the transferable fact isn't Capricor's. It's that the agency will re-cut your pivotal dataset in public, forty-eight hours before your panel, and let the market do the pricing. Every adcomm prep plan and every financing calendar behind one should now assume that's the normal case, not the bad one.

And while all of that was happening, somebody was writing a very large check.

They were. argenx is buying Forte Biosciences. Seventy-seven dollars a share, all cash, approximately two point two billion in total equity value — announced this morning. STAT puts the premium at forty-one percent to Friday's close. What they're getting is FB102, described in the announcement as a first-in-class anti-CD122 antibody in mid-stage development, with clinical proof-of-concept in vitiligo and celiac disease. We've tracked argenx for months on the FcRn franchise. This is the company deliberately buying its way out of being a one-mechanism story.

And the two point two billion is being paid for one word: multiple. BioPharma Dive describes FB102 as showing early promise against multiple immunological conditions. That's the platform sentence — and it's currently attached to a single Phase 2 antibody. Vitiligo and celiac aren't adjacent. Different endpoints, different regulatory paths, different commercial machines entirely. My test hasn't moved. It's a molecule until the second indication reads out on its own protocol.

Let's bring in Marcus Webb on the structure.

That's the tell I'd have missed. Staying with the day's other big move — Legend Biotech. Ying Huang stepped down as chief executive and from the board, effective at the end of the week, after a lengthy tenure. Alan Bash, who runs the Carvykti business unit, is interim CEO. The board has opened a search. Huang stays on as an advisor through August. Fierce cites pressure on two fronts — competition to Carvykti, and geopolitical risk given the company's China ties. We flagged that pressure building here a week ago.

Promoting the Carvykti unit head into the interim chair is the most legible thing the board could have done. It says the near-term job is defending the franchise, full stop. It also concedes that nobody currently in the building has a persuasive answer to what Legend is beyond that one product.

So the permanent hire is the actual disclosure. Whoever takes that seat tells you whether the board thinks it's running a commercial defense or a rebuild — and those are two completely different companies.

On the regulatory side, Wednesday's session is the Cellular, Tissue and Gene Therapies Advisory Committee, and per the FDA's own notice it streams live. That detail matters more than it sounds. The transcript becomes reference material for every cell therapy sponsor writing a pivotal protocol this year. And the substance underneath it is PUL 2.0 — an upper-limb functional scale. In a largely non-ambulatory Duchenne population, that's the endpoint that's available. It isn't necessarily the one the agency wants to hang an approval on. That gap is the real subject of the meeting.

And it becomes a capital question fast. Any cell therapy sponsor that watched a sixty-seven percent single-day move triggered by paperwork just repriced its own pre-panel risk. So did everyone underwriting them.

What I'll be listening for Wednesday is drift. If the discussion stays on Capricor, it's contained. If it drifts onto the endpoint itself — whether a functional scale can carry a pivotal claim in this population — then every sponsor running that design has to reopen a statistical analysis plan they thought was closed. That blast radius is considerably wider than a single stock taking a steep hit.

Looking ahead. The committee meeting, coming up midweek, will be live-streamed, and Capricor has already posted a portion of its slides publicly to frame the room in advance. That's an unusual move and worth noting on its own. On argenx and Forte, watch the tender offer mechanics and the third-quarter close. At Legend, the search is open and the clock on it started Friday.

One addition on Wednesday. Watch whether any panel member takes up the analysis plan dispute directly, or whether it gets filed as a company grievance and set aside. That single procedural choice decides whether Capricor gets a hearing on the merits or a formality with a vote at the end.

And if it's a formality, then today's sixty-seven percent wasn't the market being wrong. It was the market being early.

And that is your Pharma Closeout for Monday, July 27th — Capricor gutted by a briefing document, argenx paying two point two billion in cash for Forte and FB102, and Legend Biotech losing a chief executive on a Friday afternoon. All of that before the week's actual catalyst on Wednesday. Follow wherever you listen and tomorrow's briefing lands on its own.

I'm spending tonight with Capricor's posted slides next to what the reviewers actually wrote. That side-by-side will tell us more about Wednesday than anything either side says between now and then. Have a good evening.